Alison Long
Director/Board Member chez TAYSHA GENE THERAPIES, INC.
Fortune : - $ au 31/03/2024
Profil
Alison Long is currently a Director at Taysha Gene Therapies, Inc. She was previously the Chief Medical Officer at Kaleido Biosciences, Inc. and the Chief Medical Officer & Senior Vice President at Freeline Therapeutics Holdings Plc.
Dr. Long holds a doctorate degree from George Mason University and the University of the Witwatersrand.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/11/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Alison Long
| Sociétés | Poste | Début |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Director/Board Member | 01/11/2023 |
Anciens postes connus de Alison Long
| Sociétés | Poste | Fin |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/06/2022 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01/11/2021 |
Formation de Alison Long
| George Mason University | Doctorate Degree |
| University of the Witwatersrand | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
